Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.

Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.

The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.

In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.

The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech, Inc.
Moleculin Biotech logo
Country United States
Founded 2015
IPO Date Jun 2, 2016
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Walter Klemp

Contact Details

Address:
5300 Memorial Drive, Suite 950
Houston, Texas 77007
United States
Phone (713) 300-5160
Website moleculin.com

Stock Details

Ticker Symbol MBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001659617
CUSIP Number 60855D200
ISIN Number US60855D2009
Employer ID 47-4671997
SIC Code 2834

Key Executives

Name Position
Walter V. Klemp Co-Founder, Chairman, President and Chief Executive Officer
Jonathan P. Foster CPA Executive Vice President and Chief Financial Officer
Dr. Donald H. Picker Ph.D. Chief Scientific Officer
Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board
Dr. John Paul Waymack M.D., Sc.D. Senior Chief Medical Officer
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer of New Products
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. European Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 25, 2024 S-8 Securities to be offered to employees in employee benefit plans
Oct 25, 2024 8-K Current Report
Oct 17, 2024 8-K Current Report
Oct 7, 2024 8-K Current Report
Oct 2, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Sep 16, 2024 8-K Current Report
Sep 16, 2024 8-K Current Report
Sep 13, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 13, 2024 DEF 14A Other definitive proxy statements